Clinical features and treatment outcome of non-Hodgkin’s lymphoma-associated hemophagocytic syndrome:report of32cases

Jie HAO,Ming-Zhe ZHAO,Zhan-Yun LIU,Zhen-Yu LIU,Liang-Qun LI,Ben-Tian ZHANG,Qiong GUO,Yu CHEN,Wei-Li ZHAO,Li WANG
DOI: https://doi.org/10.11915/j.issn.1671-5403.2015.11.187
2015-01-01
Chinese Journal of Multiple Organ Diseases in the Elderly
Abstract:ObjectiveTo investigate the clinical features, treatmentefficiency and prognosis of non-Hodgkin’s lymphoma-associated hemophagocytic syndrome (LAHS).MethodsClinical data of 32 LAHS patients treated intheDepartment ofHematologyinRuijin Hospitalfrom January 2005 to December 2013were retrospectively collected. Kaplan-Meiersurvival analysiswas used to estimate survival functions. Cox regression modelwasperformedto evaluate 14 factors affectingsurvival. Results Among the 32 patients, 7(22%)were of high risk(4-5 points)according to the international prognostic index (IPI). T-cell or natural killer (NK)/T cell subtypes were the most predominantpathologicalsubtypes. Of the 23 patients who were treated with the regimenscontainingetoposide, 8 patients (35%) achieved complete remission (CR) and 6 patients (26%) partial remission (PR), withanoverall response rate (ORR)of 61%. Of the 9 patients who were treated with the regimens without etoposide, only 1 patient (11%) achieved CR and none PR (0%). The regimens with etoposide were moreefficient than those without etoposide (Chi square=4.874,P=0.036). The median overall survival (OS) of the cohort was 122 days (95%CI=79.0165.0). Multivariate analysis showed that CRnon-achievement(P=0.001)and subnormal hypofibrinogenemia (<1.5g/L,P=0.031) were the predictive parameters for total survival rate.ConclusionLAHS is usuallyaccompanied with multi-organ dysfunctions, and has rapid progression and poor prognosis. Regimens containing etoposide significantly improve the treatment outcome of those patients.
What problem does this paper attempt to address?